The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?

Expert Opinion on Biological Therapy
Ana Lorenzo-Vizcaya, D A Isenberg

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by multiple pathologies in which sustained inflammatory activity leads to progressive tissue destruction and organ damage. One of the main proinflammatory cytokines playing a key role in autoimmune diseases such as rheumatoid arthritis (RA) or SLE, is tumor necrosis factor (TNF) alpha. The introduction of TNF-alpha inhibitors revolutionized the treatment of RA and other conditions including psoriatic arthritis and ankylosing spodylitis. We review here the efficacy and safety of TNF-alpha blockers in SLE focussing on why it has not been more widely used since TNF-alpha was reported to be increased in SLE patients and to correlate with disease activity. We summarize the reported SLE cases that have received TNF-alpha blockers and the main results to date. We reflect on whether there is a case to reconsider the use of TNF-alpha blockade in SLE.

References

Nov 1, 1978·The Journal of Experimental Medicine·B S AndrewsF J Dixon
Sep 1, 1991·Clinical and Experimental Immunology·Y Deguchi, S Kishimoto
Sep 1, 1989·Clinical Immunology and Immunopathology·C GordonD Wofsy
Jan 28, 1988·Nature·C O Jacob, H O McDevitt
Jan 1, 1994·Virchows Archiv : an International Journal of Pathology·T TakemuraS Maki
Jul 10, 1999·Drugs·B Jarvis, D Faulds
Mar 22, 2002·Nature Reviews. Immunology·John J O'SheaPeter Lipsky
Apr 19, 2002·Paediatric Drugs·Luis CarreñoIndalecio Monteagudo
Sep 11, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ava J WuHugh O McDevitt
Dec 12, 2003·European Journal of Haematology·John KuruvillaSheldon C Naiman
Jun 11, 2004·Seminars in Arthritis and Rheumatism·Diana GómezJuan-Manuel Anaya
Aug 7, 2004·Annals of the Rheumatic Diseases·C ErikssonS Rantapää-Dahlqvist
Feb 1, 2005·Joint, Bone, Spine : Revue Du Rhumatisme·Jérémie SellamAndré Kahan
Sep 1, 2005·Alimentary Pharmacology & Therapeutics·F AtzeniG Bianchi Porro
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
Nov 17, 2005·Archives of Internal Medicine·Elias ZintzarasHaralampos M Moutsopoulos
Feb 21, 2006·Journal of the American Academy of Dermatology·Robert NormanJ Mark Jackson
Mar 28, 2006·Clinical Rheumatology·Sawsan J HayatMohammed Al-Oun
Jul 27, 2006·Arthritis and Rheumatism·S BernatskyR Ramsey-Goldman
Aug 18, 2006·The New England Journal of Medicine·D L Scott, G H Kingsley
Dec 30, 2006·Arthritis and Rheumatism·Martin AringerJosef S Smolen
Jan 27, 2007·Rheumatology·S BernatskyA Clarke
Apr 25, 2007·Rheumatology·R Yazdani, V V Kaushik
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Jul 17, 2007·Medicine·Manuel Ramos-CasalsMunther A Khamashta
Jan 9, 2008·Rheumatology·C WenhamC Deighton
Jan 30, 2008·Arthritis Research & Therapy·Martin Aringer, Josef S Smolen
Feb 17, 2009·Journal of the American Academy of Dermatology·Alexandra Maria Giovanna Brunasso, Cesare Massone
Apr 7, 2009·Journal of Thrombosis and Haemostasis : JTH·R H AsterD W Bougie

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.